Abstract
It is well known that hypersensitivity affects patients recently treated with scaling and root planing. Some studies have demonstrated that photobiomodulation (PBM) can alleviate dentinal hypersensitivity by modulating pain. However, to date, there is no established protocol for its application after scaling and root planning. To evaluate tooth hypersensibility after photobiomodulation in sensitive scaling and root planning treated teeth. Study design: Randomized, controlled, double-blind split-mouth clinical trial. Methods: Forty-four patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W, area 0,5cm2, 200w/cm2, 30 seconds, 3 J, 6J/cm2) and Control Group: Scaling and root planning +FBM simulation. After 7 days of scaling and root planning, all patients will be evaluated for hypersensibility. The cutoff of VAS will be 3. These patients will be included in the study. The primary outcome of the study will be the assessment of dentin hypersensitivity after 7 days of RAR measured with the visual analog scale (VAS). Also, it will be assessed the impact of oral health on the participant’s quality of life, with the OHIP-14 questionnaire. The use of analgesics (paracetamol) will be prescribed as needed and the amount of medication will be calculated. These outcomes will be evaluated after 7 days and 1 month of application. If the data are normal, they will be submitted to the ANOVA test – one way. Data will be presented as means ± SD and the p-value will be set to < 0.05.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05946265 (initial release: July 2023)
Funding Statement
The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Universidad Católica del Uruguay Comite de etica en investigacion statement number: 30052022 consent form: written
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data availability Statement- all data will be available for the readers.
Funding Statement - The project received a government grant (National Council for Scientific and Technological Development – CNPq- process: 3146682020-9). In this study the funder only will provide support and resources but will not hold ultimate authority over study design, data collection, analysis, report writing, or publication decisions, ensuring scientific integrity and independence
Conflict of interest disclosure All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) this study.
Ethics approval Statement - The project received approval from the Research Ethics Committee of Universidad Católica del Uruguay (UCU), (process: 30052022)
Patient consent Statement – All the participants included signed an Informed consent. The CI document was in writing.
Clinical trial registration: NCT05946265 (initial release: July 2023)
Dissemination policy We will disseminate the trial findings to participants, healthcare professionals, and the general public. Comprehensive data, along with results, will be shared through both complete datasets and results databases while adhering to any publication restrictions. Moreover, we are committed to facilitating potential public access to the full protocol, participant-level dataset, and statistical code. These measures emphasize our unwavering dedication to maintaining transparency
garciaolazabal{at}gmail.com
dr.luisepm{at}gmail.com
drconsolandich{at}gmail.com
anapaula{at}taboada.com.br
laurahermidabruno{at}gmail.com
federico.todeschini{at}ucu.edu.uy
pllongo{at}gmail.com
lunglasertherapy{at}yahoo.com.br
ricardosnavarro{at}gmail.com
cduran{at}uni9.pro.br
kristianneporta{at}gmail.com
raquel.mesquita{at}gmail.com
sandra.skb{at}gmail.com
larajmotta{at}uni9.pro.br
annacrth{at}gmail.com
Data Availability
Deidentified research data will be made publicly available when the study is Completed and published.
